Skip to main content
Verified Statutory Healthcare Resource — Indian Pharmacopoeia (IP) / CDSCO / PMBJP Jan Aushadhi Standards
Diabetes & Metabolism 6 min read • Last Updated: September 2026

Janumet (Sitagliptin + Metformin): DPP-4 Combination Benefits & Generic Options

Clinical breakdown of Janumet 50/500 (Sitagliptin + Metformin): incretin hormones, post-meal glucose control, weight neutrality, and patent expiry...

Statutory Medical Disclaimer & Emergency Safety Notice The pharmacological and therapeutic data presented in this educational guide is synthesized exclusively for public health literacy, academic reference, and educational purposes in conformity with the Indian Pharmacopoeia (IP 2022) and guidelines established by the Central Drugs Standard Control Organisation (CDSCO). This content does not constitute medical diagnosis, formal physician opinion, or individualized therapeutic instruction. Under the Drugs and Cosmetics Act, 1940 and the National Medical Commission (Professional Conduct) Regulations, Schedule H, H1, and X pharmaceutical formulations must be prescribed and monitored by a registered medical practitioner (RMP). Patients must not initiate, alter, or terminate any therapeutic drug regimen without formal clinical evaluation by their treating physician or a licensed healthcare professional. For acute medical emergencies, dial 112 / 108 (India) immediately.
🩺 Quick Clinical Answer

Janumet combines Sitagliptin (50mg, a DPP-4 inhibitor) and Metformin (500mg). Sitagliptin prevents the breakdown of incretin hormones (GLP-1 and GIP), which trigger the pancreas to produce insulin only when blood sugar rises after eating. This dual therapy achieves potent glucose control with negligible risk of hypoglycemia.

1. Glucose-Dependent Insulin Secretion

Unlike sulfonylureas that squeeze insulin out of beta cells continuously, Sitagliptin acts in a glucose-dependent manner: if blood sugar is normal, it stops releasing insulin, protecting against dangerous hypoglycemic crashes.

2. Post-Meal Blood Sugar Mastery

The combination controls both fasting glucose (via Metformin suppressing hepatic production) and post-prandial spikes (via Sitagliptin boosting post-meal insulin and suppressing glucagon).

3. Massive Savings Post-Patent Expiry

Following Sitagliptin patent expiration, Jan Aushadhi and generic manufacturers introduced Sitagliptin 50mg + Metformin 500mg at ₹45.00 for 10 tablets, compared to ₹320.00 for original branded Janumet (85% savings).

PMBJP Jan Aushadhi Price Transparency

Top 8 Essential Indian Medicines: Branded MRP vs. Jan Aushadhi Generic Comparison

Compare average Indian retail MRP of top branded formulations against government-certified PMBJP Jan Aushadhi bioequivalent generic prices and active salts. Verified against official PMBJP formularies, NPPA price caps, and CDSCO regulatory registries.

Brand Name Leading Manufacturer Active Salt Formulation (IP) Branded MRP Jan Aushadhi Price Savings %
Augmentin 625 Duo GlaxoSmithKline Pharmaceuticals Amoxicillin Trihydrate 500mg + Potassium Clavulanate 125mg IP ₹220.00 ₹58.00 74%
Dolo 650 Micro Labs Ltd Paracetamol (Acetaminophen) 650mg IP ₹34.00 ₹5.50 84%
Pantocid 40 Sun Pharmaceutical Industries Pantoprazole Sodium 40mg IP (Gastro-resistant) ₹155.00 ₹8.00 95%
Azithral 500 Alembic Pharmaceuticals Azithromycin Dihydrate 500mg IP ₹132.00 ₹24.00 82%
Glycomet 500 USV Private Limited Metformin Hydrochloride 500mg IP ₹24.00 ₹4.50 81%
Shelcal 500 Torrent Pharmaceuticals Elemental Calcium 500mg + Cholecalciferol (Vit D3) 250 IU IP ₹134.00 ₹16.00 88%
Telma 40 Glenmark Pharmaceuticals Telmisartan 40mg IP ₹92.00 ₹7.50 92%
Montair-LC Cipla Ltd Montelukast Sodium 10mg + Levocetirizine Dihydrochloride 5mg IP ₹210.00 ₹18.00 91%
Combined 8-Drug Essential Therapy Basket Total: ₹1,001.00 ₹141.00 85.9% Net Savings
Additional high-volume Indian medicines bioequivalent generic savings: Atorva 10 (Atorvastatin 10mg: Branded ₹110.00 vs Jan Aushadhi ₹12.00, 89% savings), Allegra 120 (Fexofenadine 120mg: Branded ₹215.00 vs Jan Aushadhi ₹32.00, 85% savings). Official Portal: PMBJP National Formulary (janaushadhi.gov.in) →

Frequently Asked Questions (Clinical & Regulatory)

Q1: Can Janumet cause pancreatitis?

DPP-4 inhibitors carry a rare caution for acute pancreatitis. Seek immediate care if you experience severe persistent abdominal pain radiating to the back.

Q2: Can Janumet be taken once daily?

Standard Janumet is taken twice daily with meals. The extended-release formulation (Janumet XR) is taken once daily with the evening meal.

Q3: What makes Metformin Hydrochloride IP the universal first-line therapy in Type 2 Diabetes?

Metformin Hydrochloride (e.g. Glycomet 500) acts primarily by activating AMP-activated protein kinase (AMPK) in hepatocytes, suppressing hepatic gluconeogenesis and enhancing peripheral insulin sensitivity without stimulating pancreatic beta cells or causing weight gain.

Q4: How do PMBJP generic diabetes medicines compare with branded formulations?

Generic Metformin, Glimepiride, and Voglibose formulations at Jan Aushadhi Kendras undergo NABL testing and provide equivalent glycemic control at 80% to 90% cost savings for chronic life-long daily management.

Q5: What is the clinical Rule of 15 for managing acute hypoglycemia?

When blood glucose falls below 70 mg/dL with adrenergic symptoms, consume 15 grams of fast-acting carbohydrate (e.g., 3 glucose tablets, 1/2 cup fruit juice, or 3 teaspoons sugar), wait 15 minutes, and re-check capillary blood glucose. Repeat if readings remain below 70 mg/dL.

MediMatch AI Clinical Pharmacology Review Board
Clinically reviewed by Dr. Vikram Anand, MBBS, MD (Clinical Pharmacology), Dr. Aditi Sharma, MD Pharmacology & Dr. Rajesh Nair, PharmD, RPh

This clinical guide is authored and reviewed in accordance with the regulatory standards of the Indian Pharmacopoeia (IP), Central Drugs Standard Control Organization (CDSCO) drug schedules, and Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) bioequivalence guidelines. All therapeutic recommendations and drug interaction warnings are cross-referenced with official statutory publications.

Official Statutory References: Indian Pharmacopoeia Commission (ipc.gov.in) → PMBJP Jan Aushadhi Portal (janaushadhi.gov.in) → CDSCO Health & Family Welfare (cdsco.gov.in) →
Digital Personal Data Protection (DPDP) Act, 2023 Statutory Health Privacy Disclosure

Under India's Digital Personal Data Protection (DPDP) Act, 2023, MediMatch AI functions as a data fiduciary committed to zero retention of private health identifiers. Browsing educational guides, reviewing active salt monographs, and executing search queries occur without tracking or commercial profiling. All client interactions with prescription readers or lab decoders execute ephemerally in volatile memory with zero server-side storage of protected health information (PHI). For inquiries regarding data fiduciary obligations, contact our Data Protection Officer at privacy@medimatchai.in.